小分子抑制SUMOylation在小鼠的初始转导期间和之后都增加了AAV载体的表达
Maria C Seleme1, Aradhana Kasimsetty2, Young Hwang2
1The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
概括
小分子SUMOylation抑制剂,如TAK-981,显著增强腺相关病毒 (AAV) 载体转基因表达. 这种方法通过增加mRNA水平来提高基因疗法的疗效,并且即使在初始的AAV转导后也可以应用.
科学领域:
- 基因治疗 基因治疗
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 基于腺相关病毒 (AAV) 的基因疗法面临由于低效的转基因表达的局限性.
- 小型泛素类修饰剂 (SUMO) 系统影响蛋白质的功能和稳定性,可能会影响AAV转导.
- 目前,通过SUMOylation增强AAV转基因表达的实用调节剂是不可用的.
研究的目的:
- 研究小分子SUMOylation抑制剂增加AAV载体转基因表达的潜力.
- 为了评估TAK-981的有效性,一个SUMOylation抑制剂,在各种细胞和动物模型中促进AAV转基因表达.
主要方法:
- 用SUMOylation抑制剂TAK-981.1治疗人类细胞 (转化和初级) 和小鼠.
- 在体外和体内评估AAV转基因表达水平.
- 分析每一个AAV载体DNA模板的mRNA水平.
主要成果:
- 在人体细胞和小鼠中,TAK-981治疗显著增加了AAV转基因表达.
- 增强的转基因表达与每个载体DNA模板的mRNA水平增加相关.
- 当TAK-981在AAV载体转导过程中或之后服用时,无论之前的暴露情况如何,都会增加AAV转基因表达.
结论:
- 小分子SUMOylation抑制剂是增强AAV转基因表达的可行策略.
- TAK-981显示了在基于AAV的基因治疗中改善结果的潜力.
- 在临床环境中,SUMOylation调节可能提供一种新的方法来提高基因疗法的疗效.
相关概念视频
01:16In-vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...